Animal ID:
RB1805-1806
|
Host:
Rabbit
|
Reactivity:
Human, Mouse
|
Buffers:
Purified rabbit polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column and eluted out with both high and low pH buffers and neutralized immediately after elution then followed by dialysis against PBS.
|
Storage:
Maintain refrigerated at 2-8ºC for up to 6 months. For long term storage store at -20ºC. Avoid repeated freeze-thaw cycles.
|
Application:
Tested by peptide-specific ELISA (1:1,000).
|
|
|
|
Immunogen:
KLH conjugated synthetic peptide comprised of amino acids 34 - 49 [CAFKDPYQQDLGIGES] of the human bone morphogenetic protein receptor type II (BMPR2) protein.
|
Accession number:
NM_001204
|
Description:
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the bone morphogenetic protein receptor type II (BMPR2). These receptors are also closely related to the activin receptors (ACVR), ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-beta proteins and activins transduce their signals through the formation of heteromeric complexes with two different types of serine/threonine kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in BMPR2 have been associated with primary pulmonary hypertension.
|
Alternative Name(s):
bone morphogenetic protein receptor type II, BMR2, PPH1, BMPR3, BRK-3, T-ALK, BMPR-II, serine/threonine kinase type II activin receptor-like kinase, BMPR2
|
References:
- Vitt UA, Mazerbourg S, Klein C, Hsueh AJ: Bone morphogenetic protein receptor type II is a receptor for growth differentiation factor-9. Biol. Reprod. 67(2): 473-480 (2002).
- Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P: The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 277(7): 5330-5338 (2002).
- Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68(1): 92-102 (2001).
- Astrom AK, Jin D, Imamura T, Roijer E, Rosenzweig B, Miyazono K, ten Dijke P, Stenman G: Chromosomal localization of three human genes encoding bone morphogenetic protein receptors. Mamm. Genome 10(3): 299-302 (1999).
- Kawabata M, Chytil A, Moses HL: Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor. J. Biol. Chem. 270(10): 5625-5630 (1995).
- Liu F, Ventura F, Doody J, Massague J: Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell. Biol. 15(7): 3479-3486 (1995).
- Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH, Rosenbaum JS: Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem. 270(38): 22522-22526 (1995).
- Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin CH, Miyazono K: Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. U S A. 92(17): 7632-7636 (1995).
|
For Research Use Only. Not for Diagnostic or Therapeutic Use.
Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Orbigen, Inc. is strictly prohibited
|
|
